We are seeking pharmaceutical partners that are interested in testing our heparin-binding domain targeting technology to improve the safety and efficacy of their drugs.  If the technology proves useful to you, GlyTag would be willing to enter into a license agreement or other suitable business relationship.

Investors:

We are pleased to discuss our technologies and lead products with interested investors.